Aripiprazole Tablet
Product Images NDC 72865-183

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 72865-183). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg (10 mg 500s)

Bottle label for Aripiprazole Tablets USP 10 mg. The label shows the brand name Aripiprazole, strength 10 mg, dosage form tablets, and package quantity of 500 tablets. It includes manufacturer information for XLCare Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc. Additional text includes storage instructions, prescription status (Rx only), and a note for pharmacists to dispense medication guides.*

FDA Label Image

15 mg (15 mg 500s)

Label for Aripiprazole Tablets, USP 15 mg oral tablets by XLCare Pharmaceuticals, Inc. The label includes NDC 72865-183-05 and states a bottle count of 500 tablets. It specifies pharmacist instructions to dispense the Medication Guide separately and storage conditions at 20 to 25°C. Manufacturer information for XLCare Pharmaceuticals and Ascent Pharmaceuticals is also visible.*

FDA Label Image

2 mg (2 mg 500s)

Label for Aripiprazole Tablets, USP 2 mg, oral tablets manufactured by XLCare Pharmaceuticals, Inc. The label includes the NDC 72865-180-05 and states the product contains 500 tablets. It notes pharmacist dispensing guidance, storage instructions, and manufacturer details for XLCare Pharmaceuticals and Ascent Pharmaceuticals.*

FDA Label Image

20 mg (20 mg 500s)

Label for Aripiprazole Tablets, USP 20 mg oral tablets, manufactured for XLCare Pharmaceuticals, Inc. The label indicates a package containing 500 tablets, with an NDC of 72865-184-05. Instructions mention dispensing a medication guide to patients and storage recommendations at controlled room temperature. Manufacturer details for both XLCare Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc. are included.*

FDA Label Image

30 mg (30 mg 500s)

Label for Aripiprazole Tablets USP 30 mg by XLCare Pharmaceuticals, Inc. The label shows the product name, strength (30 mg), dosage form (tablet), and package quantity of 500 tablets. It includes storage instructions, dispensing information, barcode, and manufacturer details for XLCare Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc.*

FDA Label Image

5 mg (5 mg 500s)

Label for Aripiprazole Tablets, USP 5 mg by XLCare Pharmaceuticals, Inc. The label indicates the NDC code 72865-181-05 and that the package contains 500 tablets. It notes the requirement for a pharmacist to dispense the medication guide separately. Storage instructions and manufacturer information are provided, including manufacturing by Ascent Pharmaceuticals, Inc.*

FDA Label Image

Fig-1 (Figure 1)

A pharmacokinetic chart showing the effect of various other drugs on aripiprazole, illustrating fold changes and 90% confidence intervals in AUC and Cmax values relative to a reference without interacting drugs. Drugs listed include CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and other drugs such as valproate, lithium, and lorazepam.*

FDA Label Image

Fig-2 (Figure 2)

A chart showing the effect of various drugs on the pharmacokinetics of dehydro-aripiprazole. It presents fold changes and 90% confidence intervals for AUC and Cmax values relative to a reference without interacting drugs. The chart includes CYP3A4 inhibitors and inducers, gastric acid blockers, and other drugs like valproate, lithium, and lorazepam.*

FDA Label Image

Fig-3 (Figure 3)

A scatter plot chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs relative to a reference without interacting drug. The x-axis represents change relative to reference from 0.5 to 3.0, while the y-axis lists different drugs including CYP2D6, dextrmethorphan, CYP2C9, 2C19, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine and its metabolite O-desmethylvenlafaxine, and escitalopram. Data points indicate pharmacokinetic parameters such as AUC, Cmax, and INR for the listed drugs.*

FDA Label Image

Fig-4 (Figure 4)

A chart titled 'Aripiprazole Fold Change and 90% CI' illustrating pharmacokinetic changes (AUC and Cmax) relative to reference values across special populations, including CYP2D6 metabolizer status, gender, age, hepatic impairment, and renal impairment. The x-axis shows change relative to reference, and data points with confidence intervals are plotted for each condition.*

FDA Label Image

Fig-5 (Figure 5)

A pharmacokinetic chart depicting Dehydro-Aripiprazole fold change with 90% confidence intervals (CI) relative to reference across various conditions including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The variables shown are AUC and Cmax fold changes compared to reference values.*

FDA Label Image

Fig-6 (Figure 6)

Kaplan-Meier curve showing the proportion of subjects with relapse over time (days from randomization) comparing Aripiprazole and placebo groups. The graph includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Fig-7 (Figure 7)

A line graph showing the proportion of subjects with relapse over days from randomization, comparing Aripiprazole to placebo. The x-axis represents days from randomization (0 to 182), and the y-axis shows the proportion with relapse (0.0 to 1.0). The graph includes two lines: a solid line for Aripiprazole and a dashed line for placebo, with placebo showing a higher relapse proportion over time. The number of subjects at risk is displayed below the x-axis for both groups at various time points.*

FDA Label Image

Fig-8 (Figure 8)

A line graph comparing the proportion of relapse over 364 days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, while the y-axis shows the proportion with relapse. The graph includes numbers of subjects at risk at various time points for both Aripiprazole and placebo.*

FDA Label Image

Struct (Structure)

Chemical structure of Aripiprazole, showing its molecular framework including chlorinated aromatic rings and heterocyclic components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.